Table 1.
Patients characteristics
| Overall n. (%) | Cohort 1 n (%) | Cohort 2 n (%) | Cohort 3 n (%) | |
|---|---|---|---|---|
| (20 Gy) | (40 Gy) | (60 Gy) | ||
| Patients | 30 (100.0) | 14 (46.7) | 9 (30.0) | 7 (23.3) |
| Gender | ||||
| Male | 12 (40.0) | 5 (35.7) | 4 (44.4) | 3 (42.9) |
| Female | 18 (60.0) | 9 (64.3) | 5 (55.6) | 4 (57.1) |
| Age, years | ||||
| Median (range) | 91 (80-96) | 88.5 (80–96) | 91 (87-95) | 88 (80-96) |
| ECOG PS | ||||
| 0–1 | 8 (26.7) | 4 (28.6) | 2 (22.2) | 2 (28.6) |
| 2–3 | 22 (73.3) | 10 (71.4) | 7 (77.8) | 5 (71.4) |
| Charlson Comorbidity Index age related | ||||
| Median (range) | 5 (4–8) | 5 (4–8) | 6 (4–6) | 5 (4–7) |
| Histotype | ||||
| Squamous Cell Carcinoma | 23 (76.7) | 8 (57.1) | 8 (88.9) | 7 (100.0) |
| Basal Cell Carcinoma | 4 (13.3) | 4 (28.6) | 0 | 0 |
| Others | 3 (10.0) | 2 (14.3) | 1 (11.1) | 0 |
| Tumor Site | ||||
| Ear, pre- and retro-auricular region | 10 (33.4) | 4 (28.7) | 4 (44.4) | 2 (28.6) |
| Eyelid-periorbital area | 5 (16.7) | 3 (21.4) | 2 (22.2) | 0 |
| Nose | 4 (13.3) | 2 (14.3) | 2 (22.2) | 0 |
| Mandibular area | 4 (13.3) | 3 (21.4) | 0 | 1 (14.3) |
| Cheek | 4 (13.3) | 1 (7.1) | 0 | 3 (42.8) |
| Forehead-temples | 3 (10.0) | 1 (7.1) | 1 (11.2) | 1 (14.3) |
| Presenting Symptomsa | ||||
| Pain | 20 (66.7) | 10 (71.4) | 6 (66.7) | 4 (57.1) |
| Bleeding | 11 (36.7) | 6 (42.9) | 3 (33.3) | 2 (28.6) |
| T stage | ||||
| 2 | 5 (16.7) | 3 (21.4) | 2 (22.2) | 0 |
| 3 | 21 (70.0) | 8 (57.1) | 7 (77.8) | 6 (85.7) |
| 4 | 4 (13.3) | 3 (21.4) | 0 | 1 (14.3) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
a
more than one symptom could be reported per patient